New vaccine trial aims to shield 3,000+ kids from deadly pneumonia
NCT ID NCT06617715
First seen Feb 01, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study tests a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine safely triggers a strong immune response against 13 types of pneumococcal bacteria, which can cause serious illnesses like pneumonia, meningitis, and ear infections. Participants will receive the vaccine and be monitored for side effects and antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Provincial Center for Disease Control and Prevention
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.